Written in Blood

Written in Blood

Research from recent issues of Blood

WIB_icon

Treating MPNs With JAK1/2 Inhibitors Increases Risks for B-Cell Lymphomas

JAK1/2 inhibitors have been used as standard and experimental treatment of myeloproliferative neoplasms (MPNs) for years, but according to research published in Blood, their...

Could Cord Blood Transplantation Cure Refractory Severe Aplastic Anemia?

In children and young adults with refractory severe aplastic anemia (SAA) without matched, unrelated donors, cord blood transplantation was associated with low rates of...

Are Strict Eligibility Criteria Keeping Patients From Clinical Trial Participation?

Eligibility criteria for clinical trials of leukemia therapies may be overly restrictive, limiting trial results’ applicability to real-world clinical practice and leading to unbalanced...
WIB_icon

Study Finds Thromboembolism Is a Frequent Complication of ALL Treatment

Adolescents and adults with acute lymphocytic leukemia (ALL) are at a “markedly” increased risk for developing thromboembolism (TE), even when treated according to the...
WIB_icon

Children With Ambiguous Leukemia Fare Better With Lymphoid-Directed Treatment

While most patients with acute leukemia have disease with a lymphoid or myeloid linage, 2 to 5 percent have “acute leukemia of ambiguous lineage”...

Can Pevonedistat Improve Azacitidine’s Activity in Older Patients With AML?

Adding pevonedistat, a first-in-class inhibitor of the NEDD8-activating enzyme (NAE), to azacitidine led to responses in patients with acute myeloid leukemia (AML), according to...
WIB_icon

Long-Term PACE Follow-Up Confirms Ponatinib’s Benefit in CP-CML

At five-year follow-up, treatment with the third-generation tyrosine kinase inhibitor (TKI) ponatinib led to deep and durable responses in patients with heavily pretreated chronic-phase...
WIB_icon

International Workshop on CLL Updates Guidelines for the Design and Conduct of Clinical Trials

Prompted by advances in the biology and treatment of patients with chronic lymphocytic leukemia (CLL), the National Cancer Institute–sponsored International Workshop on CLL has...
WIB_icon

Insights From a Pyruvate Kinase Deficiency Registry: Broad Spectrum of Severity, Broad Role for...

No guidelines exist for the diagnosis, management, and monitoring of patients with red cell pyruvate kinase (PK) deficiency – the most common glycolytic defect...
WIB_icon

Brentuximab Vedotin and CHP Combination Leads to Lasting Remissions in Peripheral T-Cell Lymphomas

Half of patients with peripheral T-cell lymphomas (PTCLs) who were treated with brentuximab vedotin in combination with CHP (cyclophosphamide, doxorubicin, prednisone) remained in remission...
Advertisement

Current Issue

July 2018 Bonus Mid-Year Edition

This bonus issue features a look at the most recent changes to Maintenance of Certification programs, highlights from recent hematology/oncology meetings, and more.